Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 Trial

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3567-3571

  Yamamoto, Daigo ^a,c   Iwase, Satoru ^b   Yoshida, Hideyuki ^a   Kuroda, Yujiro ^b   Yamamoto, Chizuko ^c   Kitamura, Kaoru ^d   Odagiri, Hiroki ^e   Nagumo, Yoshinori ^f  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c Seiko Hospital   (Japan)

^d Breast Unit   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f Nagumo Clinic   (Japan)

Author keywords

Breast cancer; JBCRN; Meloxicam; Neuropathy; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MELOXICAM; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; JAPAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORIMOTOR NEUROPATHY; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PREOPERATIVE CARE; THIAZINES; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054758749     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Iwase S, Yamamoto D, 2, Kuroda Y, Kawaguchi T, Kitamura K, Odagiri H, Teramoto S, Akazawa K and Nagumo Y: phase II trial of preoperative chemotherapy for breast cancer. JBCRN-02 trial. Anticancer Res 31: 1483-1488, 2011.
2. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ and Bartlett JM: COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 25: 671-685, 2011.
3. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L and Cristofanilli M: Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117: 61-68, 2009.
4. Haffty BG, Yang Q, Moran MS Tan AR and Reiss M: Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 71: 1006-1013, 2008.
5. Park K, Han S, Shin E, Kim HJ and Kim JY: Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 32: 1093-1096, 2006. (Pubitemid 44774393)
6. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-84, 1999. (Pubitemid 30035640)
7. Hida T, Kozaki K, ItoH, Miyaishi O, Tatematsu Y, Suzuki T, Matsuo K, Sugiura T, Ogawa M, Takahashi T and Takahashi T: Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8: 2443-2447, 2002. (Pubitemid 34753621)
8. Markman M, Kennedy A, Webster K, Kulp B, Peterson G and Belinson J: Use of low-dose oral prednisone to prevent paclitaxelinduced arthralgias and myalgias. Gynecol Oncol 72: 100-101, 1999. (Pubitemid 29045455)
9. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B and Iglesias J: Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17: 3038-3047, 1999. (Pubitemid 29470631)
10. Savarese D, Boucher J and Corey B: Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol 16: 3918-3919, 1998. (Pubitemid 29001551)
11. Takahashi T, Ueda S, Ebisawa M, Asai G and Yamamoto N: Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22: 686S, 2004.
12. Suzukia R, Yamamoto M, Sakab H, Taniguchi H, Shindoh J, Tanikawa Y, Nomura F, Gonda H, Imaizumi K, Hasegawa Y and Shimokata K: A phase II study of carboplatin and paclitaxel with meloxicam. Lung Cancer 63: 72-76, 2009.
13. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F and Choy H: A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 15: 2158-2165, 2009.
14. Bhatt RS, Merchan J, Parker R, Wu, H-K, Zhang L, Seery V, Heymach J, Atkins MB, McDermott D and Sukhatme VP: phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma. Cancer 116: 1751-1756, 2010.
15. Schmitz KJ, Callies R, Wohlschlaeger J Kimmig R, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW and Baba HA: Overexpression of cyclooxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signaling pathways. J Clin Pathol 59: 685-691, 2006. (Pubitemid 44048775)
16. Zerkowski MP, Camp RL, Burtness BA, Rimm DL and Chung GG: Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 25: 19-26, 2007. (Pubitemid 46423585)
17. Singh B, Berry JA, Shoher A, Ayers GD, Wei C and Lucci A: COX-2 involvement in breast cancer metastasis to bone. Oncogene 26: 3789-3796, 2007. (Pubitemid 46878131)
18. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA and Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005. (Pubitemid 40365350)